Armata Pharmaceuticals, Inc. $ARMP

What the company doesAI summary of filing

Armata Pharmaceuticals is a late clinical-stage biotechnology company developing bacteriophage-based therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. The company has completed three Phase 2 clinical trials and is advancing two clinical-stage product candidates: AP-PA02, an inhaled phage therapy for chronic pulmonary Pseudomonas aeruginosa infections in cystic fibrosis and non-cystic fibrosis bronchiectasis patients, and AP-SA02, an intravenous phage therapy for complicated Staphylococcus aureus bacteremia that recently completed a Phase 1b/2a study. The company generates no product revenue and is funded through research partnerships (including a $26.2 million Department of Defense award) and debt financing from its principal stockholder Innoviva. [10-K 2026-03-25]

Segments: AP-PA02 (Pseudomonas aeruginosa phage), AP-SA02 (Staphylococcus aureus phage), AP-PA03 (P. aeruginosa acute infection candidate)